Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Advanced cytoreductive surgery: American perspective.

Zivanovic O, Aldini A, Carlson JW, Chi DS.

Gynecol Oncol. 2009 Aug;114(2 Suppl):S3-9. doi: 10.1016/j.ygyno.2008.11.033. Review.

PMID:
19573703
2.

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):287-92. Epub 2007 Nov 13.

PMID:
17996927
3.

A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.

Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown CL, Barakat RR.

Gynecol Oncol. 2009 Jan;112(1):6-10. doi: 10.1016/j.ygyno.2008.10.010.

PMID:
19100916
4.

Advanced cytoreductive surgery: Asia Pacific perspective.

Crandon AJ, Obermair A.

Gynecol Oncol. 2009 Aug;114(2 Suppl):S15-21. doi: 10.1016/j.ygyno.2008.11.007.

PMID:
19573700
5.

The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.

Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, Gardner GJ, Leitao MM Jr, Levine DA, Sonoda Y, Abu-Rustum NR, Brown CL, Barakat RR.

Gynecol Oncol. 2010 Oct;119(1):38-42. doi: 10.1016/j.ygyno.2010.05.031. Epub 2010 Jul 6.

PMID:
20609464
6.

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2004 Sep;94(3):650-4.

PMID:
15350354
7.

Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer.

Einenkel J, Ott R, Handzel R, Braumann UD, Horn LC.

Int J Gynecol Cancer. 2009 Oct;19(7):1288-97. doi: 10.1111/IGC.0b013e3181a3a833.

PMID:
19823067
8.

RE: "Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers".

Fagotti A, Vizzielli G, Scambia G.

Gynecol Oncol. 2011 Jul;122(1):201; author reply 201-2. doi: 10.1016/j.ygyno.2011.02.015. Epub 2011 Mar 12. No abstract available.

PMID:
21402402
9.

Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers.

Long KC, Levinson KL, Diaz JP, Gardner GJ, Chi DS, Barakat RR, Leitao MM Jr.

Gynecol Oncol. 2011 Jan;120(1):33-7. doi: 10.1016/j.ygyno.2010.09.015. Epub 2010 Oct 13.

PMID:
20947151
10.

Cytoreductive surgery for advanced ovarian cancer.

Pölcher M, Zivanovic O, Chi DS.

Womens Health (Lond). 2014 Mar;10(2):179-90. doi: 10.2217/whe.14.4. Review.

PMID:
24601809
11.

Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer.

Kehoe SM, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, D'Angelica M, Jarnagin WR, Barakat RR, Chi DS.

Gynecol Oncol. 2009 Mar;112(3):496-500. doi: 10.1016/j.ygyno.2008.10.011. Epub 2008 Dec 17.

PMID:
19091388
12.
13.

Surgical program building in advanced ovarian cancer: European perspective.

Verleye L, Ottevanger PB, Vergote I.

Gynecol Oncol. 2009 Aug;114(2 Suppl):S10-4. doi: 10.1016/j.ygyno.2008.11.019.

PMID:
19573699
14.

Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals.

Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:11-7.

PMID:
16515561
15.

Colon resection for ovarian cancer: intraoperative decisions.

Hoffman MS, Zervose E.

Gynecol Oncol. 2008 Nov;111(2 Suppl):S56-65. doi: 10.1016/j.ygyno.2008.07.055. Epub 2008 Oct 2. Review.

PMID:
18835022
16.

Standardization of cytoreductive surgery is a precondition for clinical trials of ovarian cancer including cytoreductive surgery and/or neoadjuvant chemotherapy.

Lim MC, Park SY.

Gynecol Oncol. 2012 May;125(2):510. doi: 10.1016/j.ygyno.2012.01.014. Epub 2012 Jan 18. No abstract available.

PMID:
22266549
17.

Is minimal invasive surgery for primary and secondary debulking of ovarian/peritoneal/fallopian tube cancer going too far?

Gorostidi M.

Int J Gynecol Cancer. 2014 Sep;24(7):1138-9. doi: 10.1097/IGC.0000000000000210. No abstract available.

PMID:
25054450
18.

Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.

Chang SJ, Bristow RE.

Gynecol Oncol. 2012 May;125(2):483-92. doi: 10.1016/j.ygyno.2012.02.024. Epub 2012 Feb 23. Review.

PMID:
22366151
19.

Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.

Chi DS, Ramirez PT, Teitcher JB, Mironov S, Sarasohn DM, Iyer RB, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Brown CL, Aghajanian C, Gershenson DM, Hoskins WJ, Hricak H, Barakat RR.

J Clin Oncol. 2007 Nov 1;25(31):4946-51.

PMID:
17971592
20.

Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers.

Goto T, Takano M, Watanabe A, Miyamoto M, Kato M, Hirata J, Sasa H, Furuya K.

Int J Gynecol Cancer. 2011 Feb;21(2):263-8. doi: 10.1097/IGC.0b013e3182098002.

PMID:
21270609

Supplemental Content

Support Center